Clinical development of CJC-1295
The chemistry delivered more time. The clinical story still has an empty space where the health outcomes ought to be.
Albumin attachment
CJC-1295 has a wonderfully specific trick: it attaches to albumin, a protein already circulating in blood, and stays around much longer. In the early human study, that design produced an estimated half-life of 5.8-8.1 days. That borrowing strikes me as elegant. The molecule borrows a carrier the body already has.
The RX in this site's name suggests the distance between an interesting compound and a medicine. Here, that distance contains a stopped development programme, unanswered safety questions and an extraordinary amount of confidence about sleep and muscle. I credit the chemistry with solving a real problem; that catalogue of benefits leaves me unconvinced.
The original albumin-conjugation paper gives the engineering a proper beginning. The discontinued patient trial gives the story its unfinished ending. Between them are findings worth understanding on their own terms.
CJC-1295 peptide structure
CJC-1295 is a synthetic GHRH analog: a modified version of part of growth-hormone-releasing hormone, which prompts the pituitary gland to release growth hormone. The peptide is built on a 29-amino-acid fragment. Changes at positions 2, 8, 15 and 27 help it resist breakdown; the DAC attachment adds the ability to bind albumin. The rat and laboratory experiments explain how those changes were put to work.
Growth hormone then stimulates the liver's production of IGF-1—a hormone involved in growth. The human studies followed these hormone changes. Their central achievement was a prolonged biological response, with the normal pulses of growth hormone still present.
The name splits in two
The published long-acting compound and the short-acting substance often called “CJC-1295 no-DAC” travel under almost the same name. Modified GRF (1-29), the no-DAC form, has the stabilising substitutions but lacks the albumin-binding part. That difference changes the duration substantially.
I resent the confusion caused by that missing suffix. A precise result can become a loose claim simply by losing “DAC” on its way to the next page. The comparison of the forms starts with that small omission and follows the consequences.
CJC-1295 benefits: clinical endpoints
In Teichman and colleagues’ healthy volunteers, growth hormone rose 2- to 10-fold for 6 days or more. IGF-1 rose 1.5- to 3-fold for 9-11 days; after multiple doses it remained above baseline up to 28 days. Those are substantial changes. The same experiments left better sleep, stronger muscles, faster recovery and lasting changes in body fat unproved.
A further hormone multiplier would add little to my enthusiasm. A trial that measures how people feel and function over time would matter much more. The research record follows the actual experiments, including the mouse finding and the small human blood-protein study that tend to disappear from the popular account.
The reports outside the studies
Sleep comes up repeatedly in community accounts. So do puffy hands, tingling fingers and irritation at injection sites. These are anecdotal accounts, not clinical evidence, and the reported benefits often arrive alongside changes in exercise, food or other substances.
The effects page gives those reports room without turning their repetition into a success rate. It also follows the biological concerns about fluid retention, blood sugar, immune reactions and sustained IGF-1 elevation.
CJC-1295 approval status
CJC-1295 has no approval for human use anywhere. A Phase 2 study in people with HIV-associated visceral obesity was discontinued, and the development programme did not advance to approval. Phase 2 is the stage at which possible benefit and safety are examined in patients.
The 2024 FDA advisory materials raised immunogenicity and other safety concerns, and the committee did not recommend CJC-1295 for the 503A compounding bulks list. It is also prohibited in sport at all times under WADA Section S2. The approval questions and published study amounts cover the practical searches that usually follow this history.